Illio,
The glory days of everything biotech are over
The market now actually wants to see revenue and not just blue sky
Until announcements actually refer to revenue and not the endless " we are looking at opportunities'', the share price will do nothing
On a pre- consolidation basis, SBN is effectively trading at 0.0005c a share...and this after about 10 years
